On December 17, 2025, Kalaris Therapeutics, Inc. disclosed that they have collaborated with a group of accredited investors to sell securities in a private placement deal, garnering around $50.0 million in total gross proceeds. This transaction precedes the company’s rigorous efforts in developing and marketing therapies for common retinal disorders.